The Multicentre International Study of oxaliplatin/5-FU/leucovorin [FOLFOX] in the Adjuvant Treatment of Colon Cancer Trial has shown that addition of oxaliplatin to infusional FU [ uorouracil] and leucovorin increased disease free and overall survival rates signi cantly. Another combination used is that of oxaliplatin and capecitabine, and hence oxaliplatinbased chemotherapy is commonly used in adjuvant treatment of colon cancer. However oxaliplatin can cause damage to nontumor bearing liver which presents as sinusoidal obstructive syndrome (SOS). These lesions are di cult to differentiate from metastasis both radiologically and clinically.The present study reports the case of a patient with oxaliplatin-induced SOS which mimicked colo-rectal liver metastasis on imaging studies. Therefore, in patients with colo-rectal cancer having received oxaliplatin-based chemotherapy, SOS may be considered as one of the causes of newly developed liver lesions, particularly if they possess representative ndings of oxaliplatin-induced SOS and the lesions do not demonstrate FDG uptake on PET-CT.
Conclusion:Thorough clinical knowledge of imaging ndings and thus identi cation of focal SOS may help in preventing overtreatment and avoiding potentially morbid surgeries.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.